Clinical Trial Update: Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update of peginterferon alfa-2a plus ribavirin plus amantadine for chronic hepatitis C; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)
• amantadine (amantadine)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: HCV Infection, Hepatitis C, Chronic | Phase 3 | Status: COMPLETED